CONTENT ANALYSIS OF THE RANGE OF ANTINEOPLASTIC DRUGS REGISTERED IN THE REPUBLIC OF UZBEKISTAN

Аннотация

This article presents a comprehensive content analysis of antineoplastic drugs registered in the Republic of Uzbekistan between 2022 and 2024. Based on the The State Register of Medicines and medical devices and medical equipment approved for use in medical practice of the Republic of Uzbekistan (the State Register), the study focuses on pharmacotherapeutic groups L01, L02, L03, and L04 according to the ATC classification. The number of registered trade names, the proportion of imports, and domestic production were evaluated. Special attention was given to alkylating agents, antimetabolites, taxanes, antitumor antibiotics, and targeted therapies. The study identifies key international nonproprietary names with stable or declining registration dynamics and highlights gaps in the current pharmaceutical supply. Findings emphasize the country's reliance on foreign suppliers, especially for high-tech drugs, and suggest directions for localization and import substitution to strengthen pharmaceutical self-sufficiency.